Homology Medicines, a preclinical biotech developing a gene therapy delivery platform for rare diseases, raised the proposed deal size for its upcoming IPO on Tuesday.
The Bedford, MA-based company now plans to raise $135 million by offering 9 million shares at a price range of $14 to $16. The company had previously filed to offer 6.7 million shares at a range of $14 to $16. At the midpoint of the revised range, Homology Medicines will raise 35% more in proceeds than previously anticipated.
Homology Medicines was founded in 2015 And booked n/a in sales for the 12 months ended December 31, 2017. It plans to list on the Nasdaq under the symbol FIXX. BofA Merrill Lynch, Cowen & Company and Evercore ISI are the joint bookrunners on the deal. It is expected to price during the week of March 26, 2018.
